SecBot SecBot
PRESS-RELEASE ·Filed Apr 10, 2026

ANVS

Annovis Bio Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The stock may react negatively to the EPS miss and dilution, but the financing secures funding through the pivotal 2027 data readout, reducing near-term liquidity risk, monitor enrollment progress and upcoming trial updates.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.59
T+0 close · Apr 10, 2026 · via day close
Latest settled
+20.75%
T+60 · $1.92
Vs SPY
+10.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 10 $1.59entry
  2. T+1 · 7mo ago +4.40%α +3.43% · $1.66
  3. T+5 · 7mo ago +17.61%α +13.11% · $1.87
  4. T+20 · 6mo ago +42.14%α +33.61% · $2.26
  5. T+60 · 4mo ago +20.75%α +10.43% · $1.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross proceeds from a public offering, extending its cash runway to Q2 2027 and fully funding its path to a Phase 3 Alzheimer's data readout and NDA submission for buntanetap.

Key Financial Metrics

EPS
−$0.39
est −$0.36 · -8.3%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Reported EPS of $-0.39, missing consensus by $-0.03 (-8.3%)
  • No revenue reported for the period
  • Closed $10M underwritten public offering, extending cash runway to Q2 2027
  • Alzheimer's Phase 3 trial 75% enrolled; 6-month symptomatic data readout expected Q1 2027
  • FDA to accept integrated safety data from both AD and PD trials for NDA submission
  • Parkinson's open-label study 28% enrolled since February 2026

Financial Impact

Dilutive offering of $10M at a loss-making stage; EPS miss of 8.3% but cash secured for key milestones

epscash runwaydilution

Risk Factors

  • Dilution from $10M public offering
  • No revenue and continued losses; dependence on trial outcomes
  • Clinical trial delays or negative data could derail NDA timeline

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3271713

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026